Abstract. Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma) is a rare neuroendocrine tumour that most often originates from pancreatic islet cells and affects one in ten million individuals per year. In adults, it develops most commonly in the fortieth year of life with a sparse female predominance. Excessive VIP secretion induces refractory watery diarrhoea, hypokalemia and achlorhydria. Other symptoms include hyperglycemia (20‑50%), hypercalcaemia (25‑50%), hypochlorhydria (20‑50%) and flushing (15‑30%). VIP plasma levels are increased in almost all patients with VIPoma, and, together with profusing secretory diarrhoea, it is sufficient to establish the diagnosis. Moreover, the majority of VIPomas are malignant or have already metastasised at the time of diagnosis. The treatment of the neoplasm comprises medical management and surgery. While surgery remains the gold standard of treatment, peptide receptor radionuclide therapy represents one of the most effective and well‑tolerated treatment options. The average survival rate of patients with VIPoma is 96 months. The objective of this review was to summarise all features of pancreatic VIPoma, as well as present novel treatment approaches for this rare neoplasm.

Contents
1. Introduction
2. Epidemiology
3. Aetiology and pathogenesis
4. Clinical manifestations
5. Diagnosis
6. Treatment
7. Prognosis
8. Conclusion

1. Introduction

Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma), also known as Verner‑Morrison syndrome, is a neuroendocrine tumour (NET) secreting VIP in an uncontrolled manner. Werner and Morrison first described this syndrome in 1958, reporting two patients with profuse watery diarrhoea leading to hypokalemia and death from shock and dehydration (1). Other names for this syndrome include pancreatic cholera (1) and WDHA syndrome (watery diarrhoea, hypokalemia, achlorhydria) due to the most common symptoms (2).

2. Epidemiology

VIPomas are rare tumours that comprise <10% of all pancreatic endocrine tumors (PETs) with an estimated incidence of 1/10,000,000 individuals per year (3). In total, 95% of VIPomas occur in solitary forms, although they likewise appear on the grounds of multiple endocrine neoplasia type 1 (MEN‑1) syndrome (4). In adults, they develop most commonly in the fortieth year of life with a sparse female predominance (male:female ratio of 1:3) (5). In children, the diagnosis is generally performed between 2 to 4 years of age (6). The majority of VIPomas are intrapancreatic and are observed in the body and tail of the pancreas, while 25% are found in the pancreatic head (7). Nevertheless, there are cases of a neoplasm with extra‑pancreatic origin, such as the bronchus, colon, liver, sympathetic nerve chains, pituitary and thyroid glands (8). In infants, on the other hand, these tumours commonly arise in the adrenal glands and sympathetic ganglia (9).

3. Aetiology and pathogenesis

A VIP is a 28‑amino‑acid polypeptide which was formerly isolated from the intestine in 1970 (10). It is a neurohormone that adheres to receptors on intestinal epithelial cells and induces the activation of adenylate cyclase and cAMP production. This pathway initiates the excretion and suppresses the reabsorption of sodium, chloride, potassium and water in the
In addition, in one case reported in the literature, a patient with VIPoma had increased dopamine levels, implying that neuroendocrine cells can secrete both catecholamines, as well as pancreatic peptides (24).

There is a significant advantage of imaging studies for the establishment of diagnosis (25,26). CT is essential in determining the size, the location of the tumour origin, the involvement of nearby structures, vessels, lymph nodes and the presence of calcification (6). VIPomas >3 cm in diameter can be efficiently recognised by CT scans (4). MRI can obtain neoplasms as small as 1 cm in diameter and are useful for the assessment of spinal tumours (27). More novel imaging with PET-CT Gallium-68 dotatate is 97% sensitive for the detection of VIPomas, while the responsiveness of contrast-enhanced CT and MRI is at 80 and 85%, respectively (28).

There are high amounts of somatostatin receptors in up to 90% of pancreatic neuroendocrine tumors (PNETs). Thus, somatostatin receptor scintigraphy applying radiolabeled somatostatin analogue octreotide or lanreotide is a beneficial approach for the identification of hidden metastases (4).

Additional methods comprise endoscopic ultrasound, which helps to define the precise extent of the disease, as well as to perform the biopsy of the lesion. Immunohistochemically, VIPomas stain positively for VIP, somatostatin, neuron-specific enolase, chromogranin A, synaptophysin and cytokeratin (29).

## 6. Treatment

The treatment of VIPomas comprises medical supervision and surgery (Fig. 1). Initial therapeutic control is intended principally for the suppression of the symptoms of the disease. It includes a rapid substitution of fluids and electrolytes to prevent dehydration and electrolyte abnormalities, and to restore the acid-base balance. The additional administration of glucocorticoids is performed in patients who are insensitive to somatostatin analogues (30).

Various studies on functional NETs have proven that managing excessive hormone levels is essential to lowering both the morbidity and mortality of patients (31,32). Somatostatin is a peptide that restrains the secretion of a wide range of hormones, and somatostatin analogues (octreotide, lanreotide and pasireotide) can reproduce its effect on the cell membrane receptors (7,33).

VIPomas, as well as the majority of NETs, usually express somatostatin receptors on their surface; somatostatin will adhere to these receptors, thus inhibiting hormone excretion from the tumour cells. Somatostatin analogues are competent in both regulating the symptoms and growth of the neoplasm (34). The CLARINET (Controlled study of Lanreotide Antiproliferative Response In Neuroendocrine Tumors) trial published in 2014, demonstrated the anti-proliferative efficacy of the somatostatin analogue, lanreotide, in patients with NETs (34). Octreotide is a synthetic long-acting SST analogue that efficiently hinders VIP discharge from tumour and has been approved by the FDA for treatment of VIPomas (35). However, long-term treatment with octreotide may result in drug resistance, leading to the administration of extremely high doses for the achievement of a desirable effect (36,37). In patients who exhibit a reduced efficacy of somatostatin, interferon-α can be introduced with octreotide to ameliorate symptoms and promote tumour regression (38). The general adverse effects of somatostatin

## 5. Diagnosis

A previous study on 41 cases from the Chinese literature revealed that the average time from the manifestation of symptoms to final diagnosis was >15 months, although patients experience a range of distinguishing signs (20). By definition, VIP plasma levels are increased in almost all patients with VIPoma (4). The diagnosis of the neoplasm is confirmed in patients with secretory diarrhoea commonly >700 ml/day with a serum VIP level >200 pg/ml (reference range is <190 pg/ml) (21). In order to verify the diagnosis, it is essential to renew the VIP levels' test, as, during the incidents of diarrhoea, plasma VIP levels remain within the normal range (22). Amid children, catecholamine amounts should also be estimated.

Supplementary blood laboratory analyses include hypochlorhydria, hypokalemia, hypercalcemia, hyperglycemia and hypomagnesemia. Moreover, high blood urea nitrogen levels are associated with renal insufficiency (11). Of note, in 66% of patients, the levels of gastrin and insulin are also elevated (23). In addition, in one case reported in the literature, a patient
analogue treatment comprise indigestion, vomiting, bloating, diarrhoea with steatorrhea following fat malabsorption, as well as mild glucose intolerance; nonetheless, symptoms tend to fade over time (34).

Surgery is recommended by The World Health Organization for all localized PNETs, regardless of the size (39). The type of surgery depends essentially on tumour localization and size, and leads to curative results in 40% of patients (40,41). A total surgical resection comprises the extraction of the primary mass, as well as all distal metastases to the lymph nodes. The pancreatic body and tail are resected during distal pancreatectomy, which can be achieved with or without splenectomy (42). A pancreaticoduodenectomy is a standard approach for a neoplasm with a location in the pancreatic head. For tumours which are <2 cm in size, parenchyma-sparing surgery, such as the enucleation of the tumour, is also an option. It conserves a considerable amount of pancreatic tissue and maintains sufficient endocrine and exocrine function of the pancreas as opposed to conventional surgery (43). Tumour debulking is not a curative procedure, although it benefits symptom control and prolongs patient survival (12).

Norton et al described 20 patients with advanced NETs to whom aggressive surgery had been done. The postoperative complication rate was 30% with no operative deaths (44). Metastases have also been noted in 60% of cases at the time of neoplasm detection (23) and most commonly arise in the liver, kidney, lymph nodes and bones (45). In cases of hepatic metastases, surgical resection of the liver is designated for patients without diffuse involvement of both lobes, diminished liver functions, extrahepatic metastases, or advanced neuroendocrine carcinoma (46). In particular, for patients with metastasis predominantly in the liver, debulking surgery

Figure 1. Treatment of VIPoma. VIPoma, vasoactive intestinal peptide secreting tumour.
can be suggested (46). In cases of small metastases (<3 cm), radiofrequency ablation and cryoablation are a common choice of treatment (47). Additionally, ablation can be applied mutually with surgical resection to bypass hepatectomy. In patients with inoperable liver metastases, liver transarterial chemoembolization (TACE) has emerged as a palliative treatment procedure (40). Still, there is a great hazard of perihepatic sepsis and liver abscess associated with liver-directed therapy (48).

For selected patients, for whom medical treatment is not an option, liver transplantation can be considered. The selection standards for liver transplantation suggested by Mazzaferro et al include a recipient age <55 years, no evidence of disease recurrence for at least 6 months during the pre-transplantation period, the extraction of all extra-hepatic metastases preceding liver transplantation and an involvement of liver parenchyma <50% (49). Gedaly et al in the retrospective report of the UNOS database revealed that 150 orthotopic liver transplants (OLTs) (amidst 87,820 ones performed between 1998 and 2008), were performed for metastatic NETs. The average recipient age was 45 years. The overall survival rate was 81% at 1 year, as opposed to 65% at 3 and 49% at 5 years following transplantation (50). In the meta-analysis by Mâthâ et al comprising 89 patients with NETs undergoing OLT, the authors indicate a 1-year survival rate of 71%, together with 55%, and 44% at 3 and five years, respectively (51). The comprehensive systematic review of 64 cases revealed that liver transplantation resembles to provide a survival benefit amid patients with diffuse liver metastases; nevertheless, a high incidence of tumour recurrence rate implies that the strict selection of patients is critical (52).

Resection of the primary mass in cases of inoperable metastatic cancer is still controversial. Data from a previous systematic review determined that the main benefit of primary tumour resection (PTR) is to alleviate manifestations caused by the primary tumour, histologically verify the diagnosis and potentially improve overall survival. Additionally, PTR was safe with a low perioperative risk of mortality (53). However, due to the scarcity of randomized controlled trials, the decision to implement PTR, particularly in asymptomatic patients with the inoperable metastatic condition, should still be made on an individual basis (54).

Everolimus (Afinitor) is an oral mammalian target of rapamycin (mTOR) inhibitor. It is applied as second-line therapy for patients with advanced neoplasms. In the RAD001 in Advanced Neuroendocrine Tumors-3 (RADIANT-3) trial, everolimus revealed the reduction of disease-related hormonal symptoms and exhibited an extended average progression-free survival (55).

Sunitinib is an inhibitor of the vascular endothelial growth factor (VEGF) pathway, which was accepted as a therapeutic approach for patients with non-surgical, progressive metastatic NETs. Even though it does not significantly lengthen progression-free survival (56), sunitinib achieves complete, rapid and sustained anti-secretory effects (57).

Additional molecularly targeted therapies include sorafenib, pazopanib, axitinib and suraftinib, multi-targeted kinase inhibitors (58), along with the combination of temsirolimus, another mTOR inhibitor, with the VEGF inhibitor, bevacizumab (59).

Cytotoxic chemotherapy includes agents, such as 5-fluorouracil (5-FU), oxaliplatin, capecitabine, temozolomide and streptozocin. Often, a combination of these will be favoured: Temozolomide with capecitabine, 5-FU/doxorubicin/streptozocin (FAS), or streptozocin with doxorubicin or 5-FU (60). Systemic chemotherapy with a streptozotocin and 5-FU mixture is a standard procedure for patients with bulky extensive growths together with extrahepatic metastases (4).

Peptide receptor radionuclide therapy (PRRT) with the radiolabeled somatostatin analogue, $^{177}$Lu-tetraazacyclododecane-tetraacetic acid-octreotide (($^{177}$Lu-DOTATATE), is a novel treatment approach for nonfunctioning PNETs (61-64). A recent trial with 34 subjects with a metastatic functioning PNET, including 5 cases of VIPoma, demonstrated that treatment with PRRT with $^{177}$Lu-DOTATATE was safe, including PR in 56% of patients and stable disease in 24% of patients. Moreover, it resulted in a reduction of syndrome-specific syndromes (71%) with a considerable improvement of QOL. Notably, there was a reduction in diarrhoea in 4 (80%) patients with a metastatic VIPoma. However, hormonal crises should be avoided during treatment (65). Other studies had shown the excellent outcome followed by a total metabolic response to the administered PRRT (66), and the improvement of the quality of life of patients with NETs (67). Ataeinia et al presented successful treatment with $^{177}$Lu-DOTATOC in a case of pancreatic tumour recurrence with comprehensive nonsurgical hepatic metastasis and IVC compression. PRRT can be counted as an advantageous treatment approach in such patients with inoperable extended metastasis nearby major vessels (68).

Lutathera® [($^{177}$Lu)Lu-DOTA-TATE] is the first approved drug therapy for PRRT. It is designated for the treatment of SSTR-positive gastroenteropancreatic NETs. Lutathera® provokes DNA breaks, leading to cell death of the tumour. The positive outcomes of the multicenter phase-III clinical trial (69), NETTER-1, led to its approval by medicines agencies in America and Europe.

7. Prognosis

The average survival rate of patients with VIPoma is 96 months (70). Ghaferi et al reported that 59% of patients at an average follow-up of 15 months were alive with no indication of disease, 23% had succumbed to the disease, and 18% were alive with the presence of the condition (9). Prognosis is largely dependent on tumour staging, surgical situation and the severity of the metastases (71). An age <40 years and >60 years, a tumour size >4 cm in diameter, the poor management of water, electrolyte and acid-base profiles, critical metastatic situation and tumour inoperability are all indicated as unfortunate prognostic circumstances (72). The mortality rate associated with VIPoma emerges from untreated WDHA syndrome leading to prolonged dehydration with critical electrolyte and acid-base imbalances, and subsequently leading to renal failure, cardiac arrest and eventually death (73).

8. Conclusion

In conclusion, VIPoma is a unique tumour and can be difficult to diagnose. If diarrhoea perseveres while fasting, VIP-producing tumours should be considered, and blood
plasma specimens should be analysed for VIP in these patients. If the VIP level is increased, the diagnosis of VIPoma should be considered. Before any palliative treatment is commenced, the patient's water and electrolyte profile should be adjusted. The neoplasm can be cured adequately by surgical resection. If an operation is undesirable, surgical debulking, somatostatin analogues can be applied. Moreover, adjuvant therapy with PRRT is an efficient and safe addition to surgery or in cases of widespread metastatic disease or unresectable primary tumour.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

LA performed the literature search, collected the data from different studies and wrote and edited this review article. The author has read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The author declares that there are no competing interests.

References


